ID: ALA1096816

Max Phase: Preclinical

Molecular Formula: C27H40N4O4

Molecular Weight: 484.64

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCCCCCCCC(=O)N1CCN(Cc2ccc(-c3noc(=O)[nH]3)cc2)C(=O)C1

Standard InChI:  InChI=1S/C27H40N4O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-24(32)31-19-18-30(25(33)21-31)20-22-14-16-23(17-15-22)26-28-27(34)35-29-26/h14-17H,2-13,18-21H2,1H3,(H,28,29,34)

Standard InChI Key:  HJJOKQOHNJVJFG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 484.64

Molecular Weight (Monoisotopic): 484.3050

AlogP: 4.90

#Rotatable Bonds: 15

Polar Surface Area: 99.51

Molecular Species: ACID

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.93

CX Basic pKa:

CX LogP: 5.37

CX LogD: 4.52

Aromatic Rings: 2

Heavy Atoms: 35

QED Weighted: 0.36

Np Likeness Score: -1.02

References

1. Meddad-Belhabich N, Aoun D, Djimdé A, Redeuilh C, Dive G, Massicot F, Chau F, Heymans F, Lamouri A..  (2010)  Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives.,  18  (10): [PMID:20417107] [10.1016/j.bmc.2010.03.049]

Source

Source(1):

• Scientific Literature